Navigation Links
FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
Date:10/19/2010

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart's two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.

"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.

"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Stockbridge says.

As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, was among the most common adverse reactions reported by patients treated with Pradaxa. Gastrointestinal symptoms, including an uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating also were reported.

Pradaxa was approved with a Medication Guide that informs patients of the
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Botox to Treat Chronic Migraine
2. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. FDA Approves Combination Contraceptive Containing a Folate
5. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
6. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
7. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
8. FDA Approves Pediatric Use of Chemical Poisoning Treatment
9. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
10. FDA Approves Vaccines for the 2010-2011 Influenza Season
11. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 ... EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") ... lock-up (the "Lock-Up") 2,353,130 common shares of the Company ... subject to the Lock-Up. Of the Common Shares released ... immediately upon release from the Lock-Up while the remainder ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... N.Y., Oct. 25, 2011 Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... surgery, neurosurgery, laparoscopic surgery, and other surgical and ... the BoneScalpel™ Ultrasonic Bone Cutting System at the ...
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods in 2010) ... to $626 million. Q3 sales grew organically by 4% with ... 4% and 2%, respectively.  Recently completed acquisitions contributed an additional ... additional 5% to reported sales growth in Q3. ...
Cached Medicine Technology:Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 2Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
(Date:2/27/2015)... 27, 2015 The winter season is here, ... expansion. When mold grows, it can be harmful to the ... avoid the consequences of mold growth with the help of ... offering tips on the best ways to prevent mold during ... makes perfect conditions for mold to thrive. Mold must be ...
(Date:2/27/2015)... Mediaplanet today announces the launch of ... that aims to bring blood health and cancer awareness ... stories in this edition go beyond the concept of ... hard-hitting advocacy, research and technological strides needed to develop ... Cancer Society, approximately every 3 minutes one person ...
(Date:2/27/2015)... “ Logical Operations ” was featured on NewsWatch as ... look at the latest and coolest technology products and ... for NewsWatch and a technology expert, conducted the review ... avoid cyber security threats. , If a person looks ... somewhere in the headlines. Well, cyber security is a ...
(Date:2/27/2015)... Miami Beach, Florida (PRWEB) February 27, 2015 ... largest non-profit organization devoted exclusively to funding innovative lymphoma ... series of education programs, outreach initiatives and patient services ... the South Florida community, returning to the greater Miami ... the La Gorce Country Club in Miami Beach on ...
Breaking Medicine News(10 mins):Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:A Way for Companies to Avoid Cyber Security Threats was Featured on NewsWatch Television on January 30, 2015 2Health News:Lymphoma Research Foundation Returns to Miami Beach For Exclusive Swirl Wine Tasting Event 2
... MSC Care Management, the industry,s leading provider of ... workers, compensation claimants nationwide, announced today that it ... company also focused on the workers, compensation industry. ... market, providing specialized workers, compensation services in four ...
... Calif. producer says they may have been mixed in ... -- The salmonella contamination behind the recall of 1 ... raw nuts involved in processing at a California plant, ... Lee Cohen, production manager for Setton International Foods Inc. ...
... information regarding organic production practices may not be explicitly ... March 31 Consumers in Ohio and elsewhere who ... produced with synthetic growth hormones will only be able ... for the organic label, according to the Organic Trade ...
... University of Delaware Study Demonstrates Economic ... WILMINGTON, Del., March 31 Members of Delaware,s business, ... for Health" (WWFH) of Delaware, a unique network of partners ... Delaware - and throughout America - at launches held at ...
... March 31 Biopure Corporation (Nasdaq: BPUR ) ... Nasdaq Stock Market. By letter dated March 24, 2009, ... its Form 10-Q for the fiscal quarter ended January 31, ... Rules. The company filed the report and received a ...
... MILLION MARK IN DONATED CAREMINNEAPOLIS, March 31 The ... 2,500 volunteer dental professionals throughout Minnesota provided their services ... afford the care. The annual Give Kids a ... dental care."It was wonderful to see a record number ...
Cached Medicine News:Health News:MSC Acquires Optimal Translation & Transportation 2Health News:Raw Nuts Could Be Salmonella Source in Pistachios: Report 2Health News:Raw Nuts Could Be Salmonella Source in Pistachios: Report 3Health News:Organic Left Standing as the Gold Standard for Consumers Looking to Avoid Food Produced With Synthetic Growth Hormones 2Health News:Organic Left Standing as the Gold Standard for Consumers Looking to Avoid Food Produced With Synthetic Growth Hormones 3Health News:Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth 2Health News:Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth 3Health News:Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth 4Health News:Biopure Receives Notices About Nasdaq Listing Compliance 2Health News:Biopure Receives Notices About Nasdaq Listing Compliance 3
... 1 Gentamicin Bone Cement, a high viscosity ... international market for over a decade, eliminates ... cement. The premixed powder helps to prevent ... Bone Cement provides the same proven characteristics ...
... for ocular precision tonometry. ,The PASCAL Dynamic ... contact tonometer for ophthalmological applications. The slitlamp-mounted ... pressure (IOP) and of ocular pulse amplitude ... few seconds. It measures pulsatile IOP directly ...
... Inserted into the punctal opening to block ... provide extended temporary relief of dry eye symptoms:, ... Dry Eye Syndrome and the dry eye components ... after ocular surgery to prevent dry eye related ...
The original tapered shaft punctum plug. Easy to insert and remove, the EaglePlug is the economical dry eye solution with a proven record of success. Designed For:, Maximal retention, Easy insertion,...
Medicine Products: